Literature DB >> 8080247

Voluntary movement at the elbow in spastic hemiparesis.

S J Fellows1, C Kaus, A F Thilmann.   

Abstract

The relative importance of hyperreflexia and paresis in disturbances of voluntary arm movement was studied in a group of patients (n = 25) with spasticity arising from a unilateral ischemic cerebral lesion. Patient performance was evaluated against data obtained from normal subjects (n = 15). Spastic patients achieved lower maximum movement velocities during flexion or extension than did normal subjects. The more marked the paresis of the elbow flexor and extensor muscles of the patients, relative to the strength of the normal subjects, the greater was this reduction in maximum velocity. For a given velocity, however, the time taken to complete a movement and the time to reach the peak velocity were normal. No relationship was found between the degree of impairment of voluntary movement and the level of passive muscle hypertonia in the antagonist. Although overactivity of the antagonist muscle may play some role in disturbance of movements made at low velocities without an opposing load, antagonist activity during movements made against a load (i.e., under more natural conditions) was at or below normal levels, even in those patients with the most marked passive muscle hypertonia. It is concluded that agonist muscle paresis, rather than antagonist muscle hypertonia, plays the dominant role in the disturbance of voluntary elbow movement following stroke.

Entities:  

Mesh:

Year:  1994        PMID: 8080247     DOI: 10.1002/ana.410360311

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Target-dependent differences between free and constrained arm movements in chronic hemiparesis.

Authors:  Randall F Beer; Julius P A Dewald; Michelle L Dawson; W Zev Rymer
Journal:  Exp Brain Res       Date:  2004-02-17       Impact factor: 1.972

2.  Factors that influence muscle weakness following stroke and their clinical implications: a critical review.

Authors:  Vicki Gray; Charles L Rice; S Jayne Garland
Journal:  Physiother Can       Date:  2012       Impact factor: 1.037

3.  Joint angular velocity in spastic gait and the influence of muscle-tendon lengthening.

Authors:  K P Granata; M F Abel; D L Damiano
Journal:  J Bone Joint Surg Am       Date:  2000-02       Impact factor: 5.284

4.  Lack of hypertonia in thumb muscles after stroke.

Authors:  Joseph D Towles; Derek G Kamper; William Z Rymer
Journal:  J Neurophysiol       Date:  2010-07-28       Impact factor: 2.714

5.  Contralesional motor deficits after unilateral stroke reflect hemisphere-specific control mechanisms.

Authors:  Saandeep Mani; Pratik K Mutha; Andrzej Przybyla; Kathleen Y Haaland; David C Good; Robert L Sainburg
Journal:  Brain       Date:  2013-01-28       Impact factor: 13.501

6.  Absence of a proximal to distal gradient of motor deficits in the upper extremity early after stroke.

Authors:  Justin A Beebe; Catherine E Lang
Journal:  Clin Neurophysiol       Date:  2008-06-20       Impact factor: 3.708

7.  Spastic velocity threshold constrains functional performance in cerebral palsy.

Authors:  Ann E Tuzson; Kevin P Granata; Mark F Abel
Journal:  Arch Phys Med Rehabil       Date:  2003-09       Impact factor: 3.966

8.  Interjoint coordination dynamics during reaching in stroke.

Authors:  M C Cirstea; A B Mitnitski; A G Feldman; M F Levin
Journal:  Exp Brain Res       Date:  2003-06-19       Impact factor: 1.972

Review 9.  The corticospinal system and transcranial magnetic stimulation in stroke.

Authors:  Monica A Perez; Leonardo G Cohen
Journal:  Top Stroke Rehabil       Date:  2009 Jul-Aug       Impact factor: 2.119

10.  Muscle weakness and lack of reflex gain adaptation predominate during post-stroke posture control of the wrist.

Authors:  Carel G M Meskers; Alfred C Schouten; Jurriaan H de Groot; Erwin de Vlugt; Bob J J van Hilten; Frans C T van der Helm; Hans J H Arendzen
Journal:  J Neuroeng Rehabil       Date:  2009-07-23       Impact factor: 4.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.